The role of oxidative stress in Rett syndrome: An overview

Annals of the New York Academy of Sciences

Volumn 1259, Issue 1, 2012, Pages 121-135

  De Felice, Claudio ^a   Signorini, Cinzia ^b   Leoncini, Silvia ^b   Pecorelli, Alessandra ^b   Durand, Thierry ^c   Valacchi, Giuseppe ^d,e   Ciccoli, Lucia ^b   Hayek, Joussef ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITÉ DE MONTPELLIER   (France)

^d UNIVERSITY OF FERRARA   (Italy)

^e Kyung Hee University   (South Korea)

Author keywords

Isoprostanes; MeCP2; Oxidative stress; Rett syndrome

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CATALASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; METHYL CPG BINDING PROTEIN 2; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; ARTICLE; AUTISM; BRAIN SIZE; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; GABAERGIC TRANSMISSION; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE THERAPY; GENOTYPE PHENOTYPE CORRELATION; HEAD CIRCUMFERENCE; HUMAN; INTELLIGENCE QUOTIENT; LIPID PEROXIDATION; MICROCEPHALY; NERVE CELL NETWORK; NERVE FIBER; NEUROLOGIC DISEASE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PSYCHOMOTOR DISORDER; QUALITY OF LIFE; RETT SYNDROME; SEIZURE; SEX DIFFERENCE; X CHROMOSOME INACTIVATION;

ANIMALIA;

EID: 84863513185     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06611.x     Document Type: Article

References (142)

1. Guy, J., H. Cheval, J. Selfridge & A. Bird 2011. The role of MeCP2 in the brain. Annu. Rev. Cell Dev. Biol. 27: 631-652.
2. Gadalla, K.K., M.E. Bailey & S.R. Cobb 2011. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy. Biochem. J. 439: 1-14.
3. Percy, A.K. 2011. Rett syndrome: exploring the autism link. Arch. Neurol. 68: 985-989.
4. Shepherd, G.M. & D.M. Katz 2011. Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: focus on Mecp2 and Met. Curr. Opin. Neurobiol. 21: 827-833.
5. Samaco, R.C. & J.L. Neul 2011. Complexities of Rett syndrome and MeCP2. J. Neurosci. 31: 7951-7959.
6. Berger-Sweeney, J. 2011. Cognitive deficits in Rett syndrome: what we know and what we need to know to treat them. Neurobiol. Learn Mem. 96: 637-646.
7. Gonzales, M.L. & J.M. LaSalle 2010. The role of MeCP2 in brain development and neurodevelopmental disorders. Curr. Psychiatry Rep. 12: 127-134.
8. Boggio, E.M., G. Lonetti, T. Pizzorusso & M. Giustetto 2010. Synaptic determinants of Rett syndrome. Front, Synaptic Neurosci. 2: 28.
9. Urdinguio, R.G., J.V. Sanchez-Mut & M. Esteller 2009. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol. 8: 1056-1072.
10. Ricceri, L., B. De Filippis & G. Laviola 2008. Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches. Behav. Pharmacol. 19: 501-517.
11. Chahrour, M. & H.Y. Zoghbi 2007. The story of Rett syndrome: from clinic to neurobiology. Neuron 56: 422-437.
12. Percy, A.K. 2008. Rett syndrome: recent research progress. J. Child. Neurol. 23: 543-549.
13. Rett, A. 1966. Uber ein eigartiges hirnatrophisches Syndrom bei Hyperammoniamie in Kindesalter. Wien Med. Wochenschr. 116: 723-738.
14. Amir, R.E., I.B. Van den Veyver, M. Wan, et al 1999. Rett syndrome is caused by mutation in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23: 185-188.
15. Neul, J.L., W.E. Kaufmann, D.G. Glaze, et al 2010. Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 68: 944-950.
16. Hagberg, B. 2002. Clinical manifestations and stages of Rett syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 8: 61-65.
17. Chao, H.T., H. Chen, R.C. Samaco, et al 2010. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468: 263-269.
18. Zoghbi, H.Y. 2009. Rett syndrome: what do we know for sure? Nat. Neurosci. 12: 239-240.
19. Miltenberger-Miltenyi, G. & F. Laccone 2003. Mutations and polymorphisms in the human methyl CpG-binding protein MECP2. Hum. Mutat. 22: 107-115.
20. Christodoulou, J., A. Grimm, T. Maher, et al 2003. RettBASE: the IRSA MECP2 variation database-a new mutation database in evolution. Hum. Mutat. 21: 466-472.
21. D'Esposito, M., N.A. Quaderi, A. Ciccodicola, et al 1996. Isolation, physical mapping and northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2. Mamm. Gen. 7: 533-535.
22. Archer, H.L., J. Evans, H. Leonard, et al 2007. Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation. J. Med. Genet. 44: 148-152.
23. Neul, J.L., P. Fang, J. Barrish, et al 2008. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology 70: 1313-1321.
24. Amir, R.E., I.B. Van den Veyver, R. Schultz, et al 2000. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann. Neurol. 47: 670-679.
25. Cheadle, J.P., H. Gill, N. Fleming, et al 2000. Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. Hum. Mol. Genet. 9: 1119-1129.
26. Huppke, P., F. Laccone, N. Kramer, et al 2000. Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients. Hum. Mol. Genet. 9: 1369-1375.
27. Hoffbuhr, K., J.M. Devaney, B. LaFleur, et al 2001. MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology 56: 1486-1495.
28. Monros, E., J. Armstrong, E. Aibar, et al 2001. Rett syndrome in Spain: mutation analysis and clinical correlations. Brain Dev. 23: S251-S253.
29. Weaving, L.S., S.L. Williamson, B. Bennetts, et al 2003. Effects of MECP2 mutation type, location and X-inactivation in modulating Rett syndrome phenotype. Am. J. Med. Genet. 118A: 103-114.
30. Bebbington, A., A. Anderson, D. Ravine, et al 2008. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology 70: 868-875.
31. Temudo, T., M. Santos, E. Ramos, et al 2011. Rett syndrome with and without detected MECP2 mutations: An attempt to redefine phenotypes. Brain Dev. 33: 69-76.
32. Downs, J., A. Bebbington, P. Jacoby, et al 2010. Level of purposeful hand function as a marker of clinical severity in Rett syndrome. Dev. Med. Child Neurol. 52: 817-823.
33. Horská, A., L. Farage, G. Bibat, et al 2009. Brain metabolism in Rett syndrome: age, clinical, and genotype correlations. Ann. Neurol. 65: 90-97.
34. Leonard, H., L. Colvin, J. Christodoulou, et al 2003. Patients with the R133C mutation: is their phenotype different from patients with Rett syndrome with other mutations? J. Med. Genet. 40: e52.
35. Wan, M., S.S. Lee, X. Zhang, et al 1999. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am. J. Hum. Genet. 65: 1520-1529.
36. Kankirawatana, P., H. Leonard, C. Ellaway, et al 2006. Early progressive encephalopathy in boys and MECP2 mutations. Neurology 67: 164-166.
37. Carney, R.M., C.M. Wolpert, S.A. Ravan, et al 2003. Identification of MeCP2 mutations in a series of females with autistic disorder. Pediatr. Neurol. 28: 205-211.
38. Watson, P., G. Black, S. Ramsden, et al 2001. Angelman syndrome phenotype associated with mutations in MECP2, a gene encoding a methyl CpG binding protein. J. Med. Genet. 38: 224-228.
39. Bahi-Buisson, N., J. Nectoux, H. Rosas-Vargas, et al 2008. Key clinical features to identify girls with CDKL5 mutations. Brain 131: 2647-2661.
40. Ariani, F., J. Hayek, D. Rondinella, et al 2008. FOXG1 is responsible for the congenital variant of Rett syndrome. Am. J. Hum. Genet. 83: 89-93.
41. Guy, J., J. Gan, J. Selfridge, et al 2007. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315: 1143-1147.
42. Gitschier, J. 2009. On the tracks of DNA methylation: an interview to Adrian Bird. PLoS Genet. 5: e1000667.
43. Ott, M., V. Gogvadze, S. Orrenius, et al 2007. Mitochondria, oxidative stress and cell death. Apoptosis 12: 913-922.
44. Calabrese, V., C. Cornelius, C. Mancuso, et al 2008. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem. Res. 33: 2444-2471.
45. Valko, M., D. Leibfritz, J. Moncol, et al 2007. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39: 44-84.
46. Fernandez-Checa, J.C., A. Fernandez, A. Morales, et al 2010. Oxidative stress and altered mitochondrial function in neurodegenerative diseases: lessons from mouse models. CNS Neurol. Disord. Drug Targets 9: 439-454.
47. Yant, L.J., Q. Ran, L. Rao, et al 2003. The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic. Biol. Med. 34: 496-502.
48. Nonn, L., R.R. Williams, R.P. Erickson, et al 2003. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol. Cell Biol. 23: 916-922.
49. Lebovitz, R.M., H. Zhang, H. Vogel, et al 1996. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc. Natl. Acad. Sci. USA 93: 9782-9787.
50. Squillaro, T., N. Alessio, M. Cipollaro, et al 2012. Reduced expression of MECP2 affects cell commitment and maintenance in neurons by triggering senescence, new perspective for Rett syndrome. Mol. Biol. Cell. 23: 1435-1445.
51. Maezawa, I. & L.W. Jin 2010. Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J. Neurosci. 30: 5346-5356.
52. Lioy, D.T., S.K. Garg, C.E. Monaghan, et al 2011. A role for glia in the progression of Rett's syndrome. Nature 475: 497-500.
53. Derecki, N.C., J.C. Cronk, Z. Lu, et al 2012. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 484: 105-109.
54. Halliwell, B. & J.M.C. Gutteridge. 1985. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219: 1-14.
55. Comporti, M., C. Signorini, G. Buonocore, et al 2002. Iron release, oxidative stress and erythrocyte ageing. Free Radic. Biol. Med. 32: 568-576.
56. Ciccoli, L., V. Rossi, S. Leoncini, et al 2004. Iron release, superoxide production and binding of autologous IgG to band 3 dimers in newborn and adult erythrocytes exposed to hypoxia and hypoxia-reoxygenation. Biochim. Biophys. Acta 1672: 203-213.
57. Papanikolaou, G. & K. Pantopoulos 2005. Iron metabolism and toxicity. Toxicol. Appl. Pharmacol. 202: 199-211.
58. Thomas, C.E. & S.D. Aust 1985. Rat liver microsomal NADPH-dependent release of iron from ferritin and lipid peroxidation. Free Radic. Biol. Med. 1: 293-300.
59. Shadid, M., G. Buonocore, F. Groenendaal, et al 1998. Effect of deferoxamine and allopurinol on non protein-bound iron concentrations in plasma and cortical brain tissue of newborn lambs following hypoxia ischemia. Neurosci. Lett. 248: 5-8.
60. Morrow, J.D., K.E. Hill, R.F. Burk, et al 1990. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA 87: 9383-9387.
61. Kadiiska, M.B., B.C. Gladen, D.D. Baird, et al 2005. Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radic. Biol. Med. 38: 711-718.
62. Jahn, U., T. Durand & J.-M. Galano 2008. Beyond prostaglandins-chemistry and biology of cyclic oxygenated metabolites formed by free-radical pathways from polyunsaturated fatty acids. Angew. Chem. Int. Ed. 47: 5894-5955.
63. Milne G.L., H. Yin, K.D. Hardy, et al 2011. Isoprostane generation and function. Chem. Rev. 111: 5973-5996.
64. Nourooz-Zadeh, J., E.H.C. Liu, E.E. Änggärd, et al 1998. F4-isoprostanes: a novel class of prostanoids formed during peroxidation of docosahexaenoic acid (DHA). Biochem. Biophys. Res. Commun. 242: 338-344.
65. Roberts, L.J., T.J. Montine, W.R. Markesbery, et al 1998. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273: 13605-13612.
66. Sastry, P.S. 1985. Lipids of nervous tissue: composition and metabolism. Prog. Lipid Res. 24: 69-176.
67. Musiek, E.S., J.K. Cha, H. Yin, et al 2004. Quantification of F-ring isoprostane-like compounds (F4-neuroprostanes) derived from docosahexaenoic acid in vivo in humans by a stable isotope dilution mass spectrometric assay. J. Chrom. B: Analyt. Technol. Biomed. Life Sci. 799: 95-102.
68. Nourooz-Zadeh, J., E.H. Liu, B. Yhlen, et al 1999. F4-isoprostanes as specific marker of docosahexaenoic acdid peroxidation in Alzheimer's disease. J. Neurochem. 72: 734-740.
69. Nourooz-Zadeh, J., B. Halliwell & E.E. Änggård 1997. Evidence for the formation of F3-isoprostanes during peroxidation of eicosapentaenoic acid. Biochem. Biophys. Res. Commun. 236: 467-472.
70. Lawson, J.A., S. Kim, W.S. Powell, et al 2006. Oxidized derivatives of omega-3 fatty acids: identification of IPF3 alpha-VI in human urine. J. Lipid. Res. 47: 2515-2524.
71. VanRollins, M., R.L. Woltjer, H. Yin, et al 2008. F2-dihomo-isoprostanes arise from free radical attack on adrenic acid. J. Lipid Res. 49: 995-1005.
72. Sofić, E., P. Riederer, W. Killian, et al 1987. Reduced concentrations of ascorbic acid and glutathione in a single case of Rett syndrome: a postmortem brain study. Brain Dev. 9: 529-531.
73. Sierra, C., M.A. Vilaseca, N. Brandi, et al 2001. Oxidative stress in Rett syndrome. Brain Dev. Suppl. 1: S236-S239.
74. De Felice, C., L. Ciccoli, S. Leoncini, et al 2009. Systemic oxidative stress in classic Rett syndrome. Free Radic. Biol. Med. 47: 440-448.
75. Valinluck V., H.H. Tsai, D.K. Rogstad, et al 2004. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res. 32: 4100-4108.
76. Wang, H., G. Yuan, N.R. Prabhakar, et al 2006. Secretion of brain-derived neurotrophic factor from PC12 cells in response to oxidative stress requires autocrine dopamine signaling. J. Neurochem. 96: 694-705.
77. Pugazhenthi, S., K. Phansalkar, G. Audesirk, et al 2006. Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal. Free Radic. Biol. Med. 40: 21-34.
78. Urdinguio, R.G., L. Lopez-Serra, P. Lopez-Nieva, et al 2008. Mecp2-null mice provide new neuronal targets for Rett syndrome. PLoS One 3: e3669.
79. Cardaioli, E., M.T. Dotti, J. Hayek, et al 1999. Studies on mitochondrial pathogenesis of Rett syndrome: ultrastructural data from skin and muscle biopsies and mutational analysis at mtDNA nucleotides 10463 and 2835. J. Submicrosc. Cytol. Pathol. 31: 301-304.
80. Kriaucionis, S., A. Paterson, J. Curtis, et al 2006. Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Mol. Cell. Biol. 26: 5033-5042.
81. Kerr, A.M. 1992. A review of the respiratory disorder in the Rett syndrome. Brain Dev. Suppl. 14: 43-45.
82. Julu, P.O., A.M. Kerr, S. Hansen, et al 1997. Functional evidence of brain stem immaturity in Rett syndrome. Eur. Child Adolesc. Psychiatry 6: 47-54.
83. Kerr, A.M. & P.O. Julu 1999. Recent insights into hyperventilation from the study of Rett syndrome. Arch. Dis. Child. 80: 384-387.
84. Julu, P.O., A.M. Kerr, F. Apartopoulos, et al 2001. Characterization of breathing and associated central autonomic dysfunction in the Rett disorder. Arch. Dis. Child. 85: 29-37.
85. Glaze, D.G., J.D. Frost, H.Y. Zoghbi, et al 1987. Rett's syndrome: characterization of respiratory patterns and sleep. Ann. Neurol. 21: 377-382.
86. Weese-Mayer, D.E., S.P. Lieske, C.M. Boothby, et al 2008. Autonomic dysregulation in young girls with Rett syndrome during nighttime in-home recordings. Pediatr. Pulmonol. 43: 1045-1060.
87. Gaultier, C. & J. Gallego 2008. Neural control of breathing: insights from genetic mouse models. J. Appl. Physiol. 104: 1522-1530.
88. Hagebeuk, E.E., R.P. Bijlmer, J.H. Koelman, et al 2012. Respiratory disturbances in Rett syndrome: don't forget to evaluate upper airway obstruction. J. Child. Neurol. Jan 30. [Epub ahead of print].
89. Voituron, N., C. Menuet, M. Dutschmann, et al 2010. Physiological definition of upper airway obstructions in mouse model for Rett syndrome. Respir. Physiol. Neurobiol. 173: 146-156.
90. Ciccoli, L., C. De Felice, E. Paccagnini, et al 2012. Morphological changes and oxidative damage in Rett syndrome erythrocytes. Biochim. Biophys. Acta 1820: 511-520.
91. De Felice, C., C. Signorini, T. Durand, et al 2011. F2-dihomo-isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome. J. Lipid Res. 52: 2287-2297.
92. Aggarwal, S., L. Yurlova & M. Simons 2011. Central nervous system myelin: structure, synthesis and assembly. Trends Cell Biol. 21: 585-593.
93. 4-neuroprostanes mediate neurological severity in Rett syndrome. Clin. Chim. Acta. 412: 1399-1406.
94. Leoncini, S., C. De Felice, C. Signorini, et al 2011. Oxidative stress in Rett syndrome: natural history, genotype, and variants. Redox Rep. 16: 145-153.
95. De Felice, C., C. Signorini, T. Durand, et al 2012. Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil. Genes Nutr. Mar 8. [Epub ahead of print].
96. Martin, LJ. 2012. Biology of mitochondria in neurodegenerative diseases. Prog. Mol Biol. Transl. Sci. 107: 355-415.
97. Wu, Z.C., J.T. Yu, Y. Li, et al 2012. Clusterin in Alzheimer's disease. Adv. Clin. Chem. 56: 155-173.
98. Corthals, A.P. 2011. Multiple sclerosis is not a disease of the immune system. Q. Rev. Biol. 86: 287-321.
99. Pagano, G. & G. Castello 2012. Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv. Exp. Med. Biol. 724: 291-299.
100. Perluigi, M. & D.A. Butterfield 2012. Oxidative stress and down syndrome: a route toward Alzheimer-like dementia. Curr. Gerontol. Geriatr. Res. 2012: 724904.
101. Tiano, L. & J. Busciglio 2011. Mitochondrial dysfunction and Down's syndrome: is there a role for coenzyme Q(10)? Biofactors 37: 386-392.
102. Campos, C., R. Guzmán, E. López-Fernández, et al 2011. Evaluation of urinary biomarkers of oxidative/nitrosative stress in children with Down syndrome. Life Sci. 89: 655-661.
103. Perluigi, M., F. di Domenico, A. Fiorini, et al 2011. Oxidative stress occurs early in Down syndrome pregnancy: a redox proteomics analysis of amniotic fluid. Proteomics Clin. Appl. 5: 167-178.
104. Hagberg, B., J. Aicardi, K. Dias, et al. 1983. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome:report of 35 cases. Ann. Neurol. 14: 471-479.
105. Hanefeld, F. 1985. The clinical pattern of the Rett syndrome. Brain Dev. 7: 320-325.
106. Rolando, S. 1985. Rett syndrome: report of eight cases. Brain Dev. 7: 290-296.
107. Witt Engerström, I. 1992. Age-related occurrence of signs and symptoms in the Rett syndrome. Brain Dev. 14(Suppl): S11-S20.
108. Meehan, R.R., J.D. Lewis, A.P. Bird 1992. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 20: 5085-5092.
109. Formichi, P., C. Battisti, M.T. Dotti, et al. 1998. Vitamin E serum levels in Rett syndrome. J. Neurol Sci. 156: 227-230.
110. Guideri F., M. Acampa, J. Hayek, et al. 1999. Reduced heart rate variability in patients affected with Rett syndrome. A possible explanation for sudden death. Neuropediatrics 30: 146-148.
111. De Bona, C., M. Zappella, J. Hayek, et al. 2000. Preserved speech variant is allelic of classic Rett syndrome. Europ. J. Hum. Genet. 8: 325-330.
112. Guy, J., B. Hendrich, M. Holmes, et al. 2001. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 27: 322-326.
113. Chen, R.Z., S. Akbarian, M. Tudor, et al. 2001. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 27: 327-33.
114. Mari, F., S. Azimonti, I. Bertani et al. 2005. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum. Mol. Genet. 14: 1935-1946.
115. Scala, E., F. Ariani, F. Mari, et al. 2005. CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms. J. Med. Genet. 42: 103-107.
116. Chahrour, M., S.Y. Jung, C. Shaw, et al. 2008. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320: 1224-1229.
117. Gonnelli, S., C. Caffarelli, J. Hayek, et al. 2008. Bone ultrasonography at phalanxes in patients with Rett syndrome: a 3-year longitudinal study. Bone 42: 737-742.
118. Neul, J.L., W.E. Kaufmann, D.G. Glaze, et al. 2010. Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 68: 944-950.
119. De Felice, C., G. Guazzi, M. Rossi, et al. 2010. Unrecognized lung disease in classic Rett syndrome: a physiologic and high-resolution CT imaging study. Chest 138: 386-392.
120. Skene P.J., R.S. Illingworth, S. Webb, et al. 2010. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 37: 457-468.
121. Chao, H.T., H. Chen, R.C. Samaco, et al. 2010. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468: 263-269.
122. De Felice, C., S. Maffei, C. Signorini, et al. 2012. Subclinical myocardial dysfunction in Rett syndrome. Eur. Heart J. Echocardiogr. Imaging.
123. Cohen, S., H.W. Gabel, M. Hemberg, et al. 2011. Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron 72: 72-85.
124. Ramocki, M.B., S.U. Peters, Y.J. Tavyev, et al. 2009. Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome. Ann. Neurol. 66: 771-782.
125. Donzel-Javouhey, A., C. Thauvin-Robinet, V. Cusin, et al. 2006. A new cohort of MECP2 mutation screening in unexplained mental retardation: careful re-evaluation is the best indicator for molecular diagnosis. Am. J. Med. Genet. A 140: 1603-1607.
126. Gomot, M., C. Gendrot, A. Verloes, et al. 2003. MECP2 gene mutations in non-syndromic X-linked mental retardation: phenotype-genotype correlation. Am. J. Med. Genet. A 123A: 129-139.
127. Colantuoni, C., O.H. Jeon, K. Hyder, et al. 2001. Gene expression profiling in postmortem Rett Syndrome brain: differential gene expression and patient classification. Neurobiol. Dis. 8: 847-865.
128. Carmeli, E., A. Bachar, R. Beiker Expression of global oxidative stress and matrix metalloproteinases is associated with rett syndrome. 2011. Neurochemical J. 5: 141-145.
129. Pecorelli, A., L. Ciccoli, C. Signorini, et al. 2011. Increased levels of 4HNE-protein plasma adducts in Rett syndrome. 2011. Clin. Biochem. 44: 368.
130. Lappalainen, R. & R.S. Riikonen 1994. Elevated CSF lactate in the Rett syndrome: cause or consequence? Brain Dev. 16:399-401.
131. Matsuishi, T., F. Urabe, H. Komori, et al. 1992. The Rett syndrome and CSF lactic acid patterns. Brain Dev. 14: 68-70.
132. Haas RH., F. Nasirian, X. Hua, et al. 1995. Oxidative metabolism in Rett syndrome: 2. Biochemical and molecular studies. Neuropediatrics 26: 95-99.
133. Armostrong, D.D. 1992. The neuropathology of the Rett syndrome. Brain Dev. Suppl. 14: S89-98.
134. Eeg-Olofsson, O., A.G. al-Zuhair, A.S. Teebi, et al. 1989. Rett syndrome: genetic clues based on mitochondrial changes in muscle. Am. J. Med. Genet. 32: 142-144.
135. Ruch, A., T.W. Kurczynski & M.E. Velasco 1989. Mitochondrial alterations in Rett syndrome. Pediatr. Neurol. 5: 320-323.
136. Dotti, M.T., L. Manneschi, A. Malandrini et al. 1993. Mitochondrial dysfunction in Rett syndrome. An ultrastructural and biochemical study. Brain Dev. 15: 103-106.
137. Coker, S.B. & A.R. Melnyk 1991. Rett syndrome and mitochondrial enzyme deficiencies. J. Child. Neurol. 6: 164-166.
138. Heilstedt, H.A., M.D. Shahbazian & B Lee Infantile hypotonia as a presentation of Rett syndrome. 2002. Am. J. Med. Genet. 111: 238-242.
139. Gibson, J.H., B. Slobedman, H. KN, et al. 2010. Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain. BMC Neurosci. 11: 53.
140. Glaze, D.G., A.K. Percy, S. Skinner, et al. 2010. Epilepsy and the natural history of Rett syndrome. Neurology 74: 909-912.
141. Buoni S., R. Zannolli, C.D. Felice, et al. 2008. Drug-resistant epilepsy and epileptic phenotype-EEG association in MECP2 mutated Rett syndrome. Clin. Neurophysiol. 119: 2455-2458.
142. Christodoulou, J. MECP2-Related Disorders Retrieved from: Last update: April 2, 2009.